Portal de Periódicos da CAPES

Exomics and immunogenics

2014; Landes Bioscience; Volume: 3; Issue: 1 Linguagem: Inglês

10.4161/onci.27817

2162-402X

Stéphane Champiat, Charles Ferté, Sophie Lebel‐Binay, Alexander Eggermont, Jean Charles Soria,

CAR-T cell therapy research

Anti-PD-1/PD-L1 antibodies are emerging as promising anticancer therapeutics. Interestingly, elevated response rates to these agents are mostly documented among patients with tumors that bear high level of somatic mutations, like melanoma or non-small cell lung carcinoma. We herein formulate the hypothesis that high levels of mutational heterogeneity in the tumor could be the key for the success of immune checkpoint-targeting therapies.